JP2020500171A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500171A5
JP2020500171A5 JP2019522726A JP2019522726A JP2020500171A5 JP 2020500171 A5 JP2020500171 A5 JP 2020500171A5 JP 2019522726 A JP2019522726 A JP 2019522726A JP 2019522726 A JP2019522726 A JP 2019522726A JP 2020500171 A5 JP2020500171 A5 JP 2020500171A5
Authority
JP
Japan
Prior art keywords
peptide fragment
amino acids
nucleic acid
vector
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500171A (ja
JP7312106B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/076179 external-priority patent/WO2018077629A1/en
Publication of JP2020500171A publication Critical patent/JP2020500171A/ja
Publication of JP2020500171A5 publication Critical patent/JP2020500171A5/ja
Priority to JP2023077867A priority Critical patent/JP2023109840A/ja
Application granted granted Critical
Publication of JP7312106B2 publication Critical patent/JP7312106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522726A 2016-10-27 2017-10-13 新しいｐｄｌ２化合物 Active JP7312106B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077867A JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16195949 2016-10-27
EP16195949.9 2016-10-27
PCT/EP2017/076179 WO2018077629A1 (en) 2016-10-27 2017-10-13 New pdl2 compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077867A Division JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Publications (3)

Publication Number Publication Date
JP2020500171A JP2020500171A (ja) 2020-01-09
JP2020500171A5 true JP2020500171A5 (enExample) 2020-11-12
JP7312106B2 JP7312106B2 (ja) 2023-07-20

Family

ID=57211335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522726A Active JP7312106B2 (ja) 2016-10-27 2017-10-13 新しいｐｄｌ２化合物
JP2023077867A Pending JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077867A Pending JP2023109840A (ja) 2016-10-27 2023-05-10 新しいｐｄｌ２化合物

Country Status (5)

Country Link
US (4) US20200024324A1 (enExample)
EP (1) EP3532487A1 (enExample)
JP (2) JP7312106B2 (enExample)
CN (1) CN109890838A (enExample)
WO (1) WO2018077629A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017341112B2 (en) * 2016-10-07 2024-06-27 Io Biotech Aps Immunogenic arginase peptides
JP7312106B2 (ja) 2016-10-27 2023-07-20 アイオー バイオテック エーピーエス 新しいｐｄｌ２化合物
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO2002002587A1 (en) * 2000-06-30 2002-01-10 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
AU2008293885A1 (en) * 2007-07-13 2009-03-05 The John Hopkins University B7-DC variants
WO2009024531A1 (en) * 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
JP2012500652A (ja) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
EP3087099A4 (en) * 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
RS61943B1 (sr) * 2015-04-17 2021-07-30 Alpine Immune Sciences Inc Imunomodulatorni proteini sa prilagodljivim afinitetima
JP7312106B2 (ja) 2016-10-27 2023-07-20 アイオー バイオテック エーピーエス 新しいｐｄｌ２化合物

Similar Documents

Publication Publication Date Title
Raghani et al. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
ES2900272T3 (es) Métodos para proporcionar ARN monocatenario
Weiner Cancer immunology for the clinician
CN108430456B (zh) 癌症疫苗
JP2019537562A5 (enExample)
JP2018509936A5 (enExample)
ES2826480T3 (es) Métodos para predecir la utilidad de neoantígenos para inmunoterapia
JP2019510001A5 (enExample)
FI3522905T3 (fi) Immunogeenisiä arginaasipeptidejä
EP2782994B1 (en) Small molecule enhancer for dendritic cell cancer vaccines
Lamichhane et al. Novel delivery systems for checkpoint inhibitors
JP7098520B2 (ja) 細胞傷害性免疫刺激性粒子及びその使用
JPWO2021182573A5 (enExample)
RU2011110376A (ru) Эпитопные пептиды hig2 и urlc10 и содержание их вакцины
JP2019527676A5 (enExample)
JP2021532791A5 (enExample)
JP2019520038A5 (enExample)
US20210355490A1 (en) Sting-dependent activators for treatment of disease
Zhang et al. A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research
JP2021525067A5 (enExample)
JP2017533182A5 (enExample)
BR112014001363A2 (pt) peptídeos mphosph1 e vacinas incluindo os mesmos
WO2018053270A1 (en) Modified natural killer cells for the treatment of cancer
Joshi et al. Novel approaches in cancer immunotherapy—A light at the end of the tunnel
Kim et al. Current status and perspective of immunotherapy in gastrointestinal cancers